Changes in Bone Mass after Discontinuation of Preexposure Prophylaxis with Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex with Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113

Academic Article

Abstract

  • © 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. Human immunodeficiency virus-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP in participants aged 15-19 years. Clinical Trials Registration. NCT01772823 (ATN 110) and NCT01769456 (ATN 113).
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Havens PL; Perumean-Chaney SE; Patki A; Cofield SS; Wilson CM; Liu N; Anderson PL; Landovitz RJ; Kapogiannis BG; Hosek SG
  • Start Page

  • 687
  • End Page

  • 691
  • Volume

  • 70
  • Issue

  • 4